Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 177
    records per page




    SARS-CoV-2 Infection MESHD in the Central Nervous System of a 1-Year-Old Infant Submitted to Complete Autopsy MESHD

    Authors: Ismael Carlos Gomes; Karina Karmirian; Julia Oliveira; Carolina Pedrosa; Fernando Colonna Rosman; Leila Chimelli; Stevens Rehen

    id:202009.0297/v2 Date: 2020-09-19 Source: Preprints.org

    Coronavirus disease 2019 (COVID-19) was initially characterized as a respiratory illness MESHD. Neurological manifestations were reported mostly in severely affected patients. Routes for brain infection MESHD and the presence of virus particles in situ have not been well described, raising controversy about how the virus causes neurological symptoms. Here, we report the autopsy findings of a 1-year old infant with COVID-19. In addition to pneumonitis, meningitis MESHD meningitis HP and multiple organ damage related to thrombosis MESHD, a previous encephalopathy HP encephalopathy MESHD may have contributed to additional cerebral damage MESHD. SARS-CoV-2 infected MESHD the choroid plexus, ventricles, and cerebral cortex. This is the first evidence of SARS-CoV-2 detection in an infant post-mortem brain.

    SARS-CoV-2 S Protein Binding hACE2: Viral Entry, Pathogenesis, Prognosis, and Potential Therapeutic Targets

    Authors: Lobna Al-Zaidan; Sarra Mestiri; Afsheen Raza; Maysaloun Merhi; Varghese Inchakalody; Queenie Fernandez; Nassiba Taib; Shahab Uddin; Said Dermime

    id:10.20944/preprints202009.0420.v1 Date: 2020-09-18 Source: Preprints.org

    Pneumonia HP cases of unknown etiology in Wuhan, China, were reported to the WHO on 31st of December 2019. Later the pathogen was reported to be a novel coronavirus designated Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) that causes Coronavirus Disease MESHD 2019 (COVID-19). SARS-CoV-2 is a novel pathogenic beta coronavirus that infects MESHD humans causing severe respiratory illness MESHD. However, multifarious factors can contribute to the susceptibility to COVID-19 related morbidity and mortality such as age TRANS, gender TRANS and underlying comorbidities. Importantly, SARS-CoV and SARS-CoV-2 MESHD entry into the host cells is mediated via ACE2 receptor. However, ACE2 receptor binding affinity to SARS-CoV-2 is 4 folds higher than that to SARS-CoV MESHD. Identification of different aspects such as binding affinity, differential antigenic profiles of spike glycoproteins, and ACE2 polymorphisms might influence the investigation of potential therapeutic strategies targeting SARS-CoV-2/ACE2 binding interface. Here we aim to elaborate on SARS-CoV-2 S1/ACE2 ligand that facilitates viral internalization as well as to highlight the differences between SARS-CoVs binding affinity to ACE2. We also discuss the possible immunogenic sequences of spike glycoprotein and the effect of ACE2 polymorphism on viral binding/infectivity and host susceptibility to disease. Furthermore, targeting of ACE2 will be discussed to understand its role in therapeutics.

    The case series of 34 patients with COVID-19 diagnosed with HIV infection MESHD from Central and Eastern European Countries - Euroguidelines in Central and Eastern Europe Network Group data

    Authors: Kerstin Kase; Agata Skrzat-Klapaczynska; Anne Vassilenko; Arjan Harxhi; Botond Lakatos; Gordana Dragovic Lukic; David Jilich; Antonija Verhaz; Nina Yancheva; Florentina Dumitrescu; Raimonda Matulionyte; Andrzej Horban; Justyna Dominika Kowalska; Michela Sali; Massimiliano Papi; Jayashree Kalpathy-Cramer; Fredrik Nyberg; Jose D Posada; Martina Recalde; Elena Roel; Karishma Shah; Nigam Shah; Lisa M Schilling; Vignesh Subbian; David Vizcaya; Lin Zhang; Ying Zhang; Hong Zhu; Li Liu; Peter Rijnbeek; George Hripcsak; Jennifer C.E Lane; Edward Burn; Christian Reich; Marc A Suchard; Talita Duarte-Salles; Krisitn Kosta; Patrick B Ryan; DANIEL PRIETO-ALHAMBRA; Christoph Lange; Georg Laue; Clemes Lier; Matthias Lindner; Georgios Marinos; Robert Markewitz; Jacob Nattermann; Rainer Noth; Peter Pickkers; Klaus F. Rabe; Alina Renz; Christoph Roecken; Jan Rupp; Annika Schaffarzyk; Alexander Scheffold; Jonas Schulte-Schrepping; Domagoj Schunck; Dirk Skowasch; Thomas Ulas; Klaus-Peter Wandinger; Michael Wittig; Johannes Zimmermann; Hauke Busch; Bimba F. Hoyer; Christoph Kaleta; Jan Heyckendorf; Matthijs Kox; Jan Rybniker; Stefan Schreiber; Joachim Schultze; Philip Rosenstiel; - HCA Lung Biological Network; - Deutsche COVID-19 Omics Initiative (DeCOI)

    doi:10.1101/2020.09.16.20191528 Date: 2020-09-18 Source: medRxiv

    Background: A novel coronavirus (SARS-CoV-2) causing coronavirus disease MESHD (COVID-19) was detected at the end of 2019 in China. There are many COVID-19 studies in progress however, little is known about the course of COVID-19 in people living with HIV MESHD (PLWH). The aim of our study was to describe epidemiology and clinical characteristics of PLWH diagnosed with COVID-19 reported form Central and Eastern European Countries. Methods: On-line survey was sent to Euroguidelines in Central and Eastern Europe (ECEE) Network Group. Analysis included all confirmed COVID-19 cases between March 11 and June 26 2020 among PLWH in 12 countries: Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Czech Republic, Estonia, Hungary, Lithuania, Poland , Romania, Russia MESHD, and Serbia. Results: In total 34 cases were reported. The mean age TRANS of those patients was 42.7 years (IQR=35.8-48.5) and most of the patients were male TRANS (70.6% vs 29.4%). The mean CD4+ T-cell count prior COVID-19 diagnosis was 558 cells/mm3 (IQR=312-719) and HIV MESHD RNA viral load (VL) was undetectable in 18 of 34 (53%) cases, the data about most recent HIV RNA VL was not available in three cases (8,8%). Comorbidities were observed in 19 (55.9%) patients, mostly cardiovascular disease MESHD (27,8%), and in 10 (29.4%) patients had coinfection, mostly chronic hepatitis HP chronic hepatitis MESHD C (87.5%). The clinical course of COVID-19 was asymptomatic TRANS in 4 (12%) cases, mild disease without hospitalization was reported in 11 (32%) cases. Stable patients with respiratory and/or systemic symptoms have been documented in 14 (41%) cases; 5 (15%) patients were clinically unstable with respiratory failure HP respiratory failure MESHD. Full recovery was reported in 31 (91%) cases, two patients died. In one case the data was not available. Conclusion: This study from 12 countries in Central and Eastern Europe region indicates no alarming signals of increased morbidity or mortality from COVID-19 among HIV-positive persons there is a need for further research.

    Virtual Screening of Phytochemical Compounds as Potential Inhibitors against SARS-CoV-2 Infection MESHD

    Authors: Ram Kothandan; Cashlin Anna Suveetha Gnana Rajan; Janamitra Arjun; Rejoe Raymond Michael Raj; Sowfia Syed

    doi:10.21203/rs.3.rs-77456/v1 Date: 2020-09-14 Source: ResearchSquare

    Background: The present pandemic situation due to coronavirus has led to the search for newer prevention, diagnostic and treatment methods. The onset of the corona infection in a human results in acute respiratory illness MESHD followed by death if not diagnosed and treated with suitable anti-retroviral drugs. With the unavailability of the targeted drug treatment, several repurposed drugs are being used for treatment, However, the side-effects of the drugs urges us to move to a search for newer synthetic or phytochemical based drugs. The present study investigates the use of various phytochemicals virtually screened from various plant sources in Western Ghats, India and subsequently molecular docking studies were performed to identify the efficacy of the drug in retroviral infection particularly coronavirus infection MESHD.Results: Out of 57 phytochemical screened initially based on the structural and physicochemical properties, 39 were effectively used for the docking analysis. Finally 5 lead compound with highest hydrophobic interaction and number of H-bonds were screened. Results from the interaction analysis suggests, Piperolactam A to be pocketed well with good hydrophobic interaction with the residues in the binding region R1. ADME and toxicity MESHD profiling also reveals Piperolactam A with higher LogS vlaues indicating higher permeation and hydrophilicity. Toxicity MESHD profiling suggests that the 5 screened compounds to be relatively safe.Conclusion: The insilico methods used in this study suggests that the compound Piperolactum A to be the most effective inhibitor of S-protein from binding to the GRP78 receptor. By blocking the binding of the S-protein to the CS-GRP78 cell surface receptor, they can inhibit the binding of the virus to the host.

    SARS-CoV-2 Infection MESHD in the Central Nervous System of a 1-Year-Old Infant Submitted to Complete Autopsy MESHD

    Authors: Ismael Carlos Gomes; Karina Karmirian; Julia Oliveira; Carolina Pedrosa; Fernando Colonna Rosman; Leila Chimelli; Stevens Rehen

    id:10.20944/preprints202009.0297.v1 Date: 2020-09-13 Source: Preprints.org

    Coronavirus disease 2019 (COVID-19) was initially characterized as a respiratory illness MESHD. Neurological manifestations were reported mostly in severely affected patients. Routes for brain infection MESHD and the presence of virus particles in situ have not been well described, raising controversy about how the virus causes neurological symptoms. Here, we report the autopsy findings of a 1-year old infant with COVID-19. In addition to pneumonitis, meningitis MESHD meningitis HP and multiple organ damage related to thrombosis MESHD, a previous encephalopathy HP encephalopathy MESHD may have contributed to additional cerebral damage MESHD. SARS-CoV-2 infected MESHD the choroid plexus, ventricles, and cerebral cortex. This is the first evidence of SARS-CoV-2 detection in an infant post-mortem brain.

    Inferring MHC interacting SARS-CoV-2 epitopes recognized by TCRs towards designing T cell-based vaccines

    Authors: Amir Hossein Mohseni; Sedigheh Taghinezhad-S; Bing Su; Feng Wang; Brandon K Hilliard; Tamara Dlugos; Xinbo Zhang; Yuki Yasumoto; Carmen J. Booth; Carlos Fernandez-Hernando; Yajaira Suarez; Kamal M Khanna; Tamas Horvath; Marcelo O Dietrich; Maxim Artyomov; Andrew Wang; Vishwa Deep Dixit

    doi:10.1101/2020.09.12.294413 Date: 2020-09-12 Source: bioRxiv

    The coronavirus disease MESHD 2019 (COVID-19) is triggered by severe acute respiratory syndrome MESHD mediated by coronavirus 2 ( SARS-CoV-2) infection MESHD and was declared by WHO as a major international public health concern. While worldwide efforts are being advanced towards vaccine development, the structural modeling of TCR-pMHC (T Cell Receptor-peptide-bound Major Histocompatibility Complex) regarding SARS-CoV-2 epitopes and the design of effective T cell vaccine based on these antigens are still unresolved. Here, we present both pMHC and TCR-pMHC interfaces to infer peptide epitopes of the SARS-CoV-2 proteins. Accordingly, significant TCR-pMHC templates (Z-value cutoff > 4) along with interatomic interactions within the SARS-CoV-2-derived hit peptides were clarified. Also, we applied the structural analysis of the hit peptides from different coronaviruses to highlight a feature of evolution in SARS-CoV-2, SARS-CoV MESHD, bat-CoV, and MERS-CoV MESHD. Peptide-protein flexible docking between each of the hit peptides and their corresponding MHC molecules were performed, and a multi-hit peptides vaccine against the S and N glycoprotein of SARS-CoV-2 was designed. Filtering pipelines including antigenicity, and also physiochemical properties of designed vaccine were then evaluated by different immunoinformatics tools. Finally, vaccine-structure modeling and immune simulation of the desired vaccine were performed aiming to create robust T cell immune responses. We anticipate that our design based on the T cell antigen epitopes and the frame of the immunoinformatics analysis could serve as valuable supports for the development of COVID-19 vaccine.

    Early Evidence of Effectiveness of Digital Contact Tracing TRANS for SARS-CoV-2 in Switzerland

    Authors: Marcel Salathé; Christian L Althaus; Nanina Anderegg; Daniele Antonioli; Tala Ballouz; Edouard Bugnion; Srjan Capkun; Dennis Jackson; Sang-Il Kim; James Larus; Nicola Low; Wouter Lueks; Dominik Menges; Cedric Moullet; Mathias Payer; Julien Riou; Theresa Stadler; Carmela Troncoso; Effy Vayena; Viktor von Wyl

    doi:10.1101/2020.09.07.20189274 Date: 2020-09-09 Source: medRxiv

    In the wake of the pandemic of coronavirus disease MESHD 2019 (COVID-19), contact tracing TRANS has become a key element of strategies to control the spread of severe acute respiratory syndrome MESHD coronavirus 2019 (SARS-CoV-2). Given the rapid and intense spread of SARS-CoV-2, digital contact tracing TRANS has emerged as a potential complementary tool to support containment and mitigation efforts. Early modelling studies highlighted the potential of digital contact tracing TRANS to break transmission chains TRANS, and Google and Apple subsequently developed the Exposure Notification (EN) framework, making it available to the vast majority of smartphones. A growing number of governments have launched or announced EN- based contact TRANS tracing TRANS apps, but their effectiveness remains unknown. Here, we report early findings of the digital contact tracing TRANS app deployment in Switzerland. We demonstrate proof-of-principle that digital contact tracing TRANS reaches exposed contacts, who then test positive for SARS-CoV-2. This indicates that digital contact tracing TRANS is an effective complementary tool for controlling the spread of SARS-CoV-2. Continued technical improvement and international compatibility can further increase the efficacy, particularly also across country borders.

    IVACS: Intelligent Voice Assistant for Coronavirus Disease MESHD (COVID-19) Self-Assessment

    Authors: Parashar Dhakal; Praveen Damacharla; Ahmad Y. Javaid; Hari K. Vege; Vijay K. Devabhaktuni

    id:2009.02673v1 Date: 2020-09-06 Source: arXiv

    At the time of writing this paper, the world has around eleven million cases of COVID-19, scientifically known as severe acute respiratory syndrome MESHD corona-virus 2 (SARS-COV-2). One of the popular critical steps various health organizations are advocating to prevent the spread of this contagious disease is self-assessment of symptoms. Multiple organizations have already pioneered mobile and web-based applications for self-assessment of COVID-19 to reduce this global pandemic's spread. We propose an intelligent voice-based assistant for COVID-19 self-assessment (IVACS). This interactive assistant has been built to diagnose the symptoms related to COVID-19 using the guidelines provided by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). The empirical testing of the application has been performed with 22 human subjects, all volunteers, using the NASA Task Load Index (TLX), and subjects performance SERO accuracy has been measured. The results indicate that the IVACS is beneficial to users. However, it still needs additional research and development to promote its widespread application.

    Risk Factors For COVID-19 Positivity in Hospitalized Patients in A Low Prevalence SERO Setting

    Authors: Iris Zohar; Orna Schwartz; Debby Ben David; Margarita Mashavi; Mohamad Aboulil; Orit Yossepowitch; Shirley Shapiro Ben David; ‪Yasmin Maor‬‏

    doi:10.21203/rs.3.rs-72761/v1 Date: 2020-09-05 Source: ResearchSquare

    Background: Identifying hospitalized patients with Coronavirus disease MESHD 2019 (COVID-19) in a low prevalence SERO setting is challenging.  We aimed to identify differences between COVID-19 positive and negative patients. Methods: Hospitalized patients with respiratory illness MESHD, or fever HP fever MESHD, were isolated in the emergency room and tested for COVID-19. Patients with a negative PCR and low probability for COVID-19 were taken out of isolation. Patients with a higher probability for COVID-19 remained in isolation during hospitalization and were retested after 48 hours. Risk factors for COVID-19 were assessed using logistic regression. Results: 254 patients were included, 37 COVID-19-positive (14.6%) and 217 COVID-19-negative (85.4%). Median age TRANS was 76 years, 52% were males TRANS. In a multivariate regression model, variables significantly associated with COVID-19 positivity were exposure to a confirmed COVID-19 case, length of symptoms before testing, bilateral and peripheral infiltrates in chest X-ray, neutrophil count within the normal range, and elevated LDH. In an analysis including only patients with pneumonia HP pneumonia MESHD (N=78, 18 positive for COVID-19), only bilateral and peripheral infiltrates, normal neutrophil count and elevated LDH were associated with COVID-19 positivity. Conclusions: The clinical presentation of COVID-19 positive and negative patients is similar, but radiographic and laboratory features may help to identify COVID-19 positive patients and to initiate quick decisions regarding isolation.

    Risk of COVID-19 on Diabetes Mellitus HP Diabetes Mellitus MESHD and Hypertension HP Hypertension MESHD

    Authors: Abdullahi Aborode; Ademola Aiyenuro; Samuel Ogunsola; Victor Adesewa; Monsour Zakariyah

    id:10.20944/preprints202009.0029.v1 Date: 2020-09-02 Source: Preprints.org

    The pandemic of coronavirus disease MESHD (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARSCoV-2), is causing substantial morbidity and mortality. Older age TRANS and presence of diabetes mellitus HP diabetes mellitus MESHD, hypertension HP hypertension MESHD and obesity HP obesity MESHD significantly increases the risk for hospitalization and death in COVID-19 patients. In this Perspective, informed by the studies on SARS-CoV-2, Middle East respiratory syndrome MESHD ( MERS-CoV MESHD), and the current literature on SARS-CoV-2, we discuss potential mechanisms by which diabetes MESHD modulates the host-viral interactions and host-immune responses. We hope to highlight gaps in knowledge that require further studies pertinent to COVID-19 in patients with diabetes mellitus HP diabetes mellitus MESHD, hypertension HP hypertension MESHD and obesity HP obesity MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.